Women who carry mutations in either the BRCA1 or BRCA2 genes are at risk for early-onset
breast cancer and are recommended to begin screening mammography at age 25 to 30 …

Purpose Recent randomized controlled trials have shown that tamoxifen and raloxifene may
prevent invasive breast cancer. This decision analysis study compares the outcomes of …

Purpose The sensitivity of magnetic resonance imaging (MRI) for breast cancer screening
exceeds that of mammography. If MRI screening reduces mortality in women with a BRCA1 …

BACKGROUND It has been suggested that BRCA‐associated breast carcinoma may often
lack a detectable preinvasive phase. To investigate this hypothesis, the authors compared …

Abstract We report the 5-and 10-year survival rate of women diagnosed with breast cancer
in the context of an annual MRI-based surveillance program. In 2001, as part of a national …

Mutations in BRCA1 and BRCA2 have been associated with an increased lifetime risk of
breast and ovarian cancers. Many of the well-recognized risk factors and risk modifiers in …

Purpose: Risk calculations for carrying BRCA1/BRCA2 mutations are based on family
history and the age of onset of cancers. However, women may carry these deleterious …

BACKGROUND: The availability of genetic testing for inherited mutations in the BRCA1
gene provides potentially valuable information to women at high risk of breast or ovarian …

Given the greatly elevated risks of contralateral breast cancer (CBC) observed in breast
cancer patients who carry mutation in BRCA1 or BRCA2, the present meta-analysis was …

BACKGROUND: Magnetic resonance imaging (MRI) has been used to supplement
screening mammography and clinical breast examination (CBE) in women who are at high …